S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 181 to 221 of 221

Issue Date	Title / Author(s) / Citation	File
2018-03	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Cancer Immunology, Immunotherapy, Vol.67 No.3, pp.459-470	DOI
2018-06	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Thoracic Cancer, Vol.9 No.6, pp.736-744	view file DOI
2018-07	The effect of hospice consultation on aggressive treatment of lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.50 No.3, pp.720-728	view file DOI
2018-08	Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Se Hyun; Kim, Yu Jung; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Esmo Open, Vol.3 No.5, p. e000332	DOI
2019	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma Kang, Seong-Ho; Keam, Bhumsuk; Ahn, Yong-Oon; Park, Ha-Ram; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog OncoImmunology, Vol.8 No.1, p. e1515057	DOI
2019-01	Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; Park, Keunchil; Kim, Hoon-Kyo; Jang, Joung Soon; Kim, Bong-Seog; Kang, Jin-Hyoung; Lee, Kyung Flee; Kim, Sang-We; Ryoo, Hun Mo; Kim, Jin-Soo; Lee, Ki Hyeong; Kwon, Jung Hye; Choi, Jin-Hyuk; Shin, Sang Won; Hahn, Seokyung; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.1, pp.119-127	view file DOI
2019-01	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors Kim, Ryul; Keam, Bhumsuk; Kim, Sehui; Kim, Miso; Kim, Se Hyun; Kim, Jin Wook; Kim, Yu Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Lee, Jong Seok; Heo, Dae Seog BMC Cancer, Vol.19 No.1, p. 19	view file DOI
2019-01	The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin Cancer Research and Treatment, Vol.51 No.1, pp.169-177	view file DOI
2019-01	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma Kim, Miso; Kim, Tae Min; Keam, Bhumsuk; Kim, Yu Jung; Paeng, Jin Chul; Moon, Kyung Chul; Kim, Dong-Wan; Heo, Dae Seog Oncologist, Vol.24 No.1, pp.20-29	DOI
2019-05	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients Yoo, Shin Hye; Keam, Bhumsuk; Ock, Chan-Young; Kim, Sehui; Han, Buhm; Kim, Ji-Won; Lee, Keun-Wook; Jeon, Yoon Kyung; Jung, Kyeong Cheon; Chung, Eun-Jae; Kwon, Seong Keun; Ahn, Soon-Hyun; Sung, Myung-Whun; Heo, Dae Seog Scientific Reports, Vol.9 No.1, p. 7680	DOI
2019-06	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors Park, Ha-Ram; Ahn, Yong-Oon; Kim, Tae Min; Kim, Soyeon; Kim, Seulki; Lee, Yu Soo; Kim, Miso; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog Cytotherapy, Vol.21 No.6, pp.603-611	DOI
2019-07	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451	DOI
2019-07	Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.951-962	view file DOI
2019-07	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP Cho, Kyoung Min; Keam, Bhumsuk; Ha, Hyerim; Kim, Miso; Jung, Jae-Woo; Song, Woo-Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kang, Hye-Ryun; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.4, pp.885-893	view file DOI
2019-07	Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer Kim, Su-Jung; Kim, Soyeon; Kim, Dong-Wan; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Lee, Yusoo; Koh, Jaemoon; Jeon, Yoon Kyung; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.1231-1240	view file DOI
2019-08	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study Jung, Minsun; Kim, Soyeon; Lee, June-Koo; Yoon, Sun Och; Park, Heae Surng; Hong, Soon Won; Park, Weon-Seo; Kim, Ji Eun; Kim, Joon; Keam, Bhumsuk; Kim, Hyun Jik; Kang, Hyoung Jin; Kim, Dong-Wan; Jung, Kyeong Cheon; Kim, Young Tae; Heo, Dae Seog; Kim, Tae Min; Jeon, Yoon Kyung Oncologist, Vol.24 No.8, pp.E740-E748	DOI
2019-09	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124	view file DOI
2019-09	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis Kim, Ryul; Keam, Bhumsuk; Hahn, Seokyung; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.5, pp.331-338.e4	DOI
2019-09	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566	DOI
2019-10	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer Kim, Yu-Jung; Keam, Bhumsuk; Ock, Chan-Young; Song, Sanghoon; Kim, Miso; Kim, Se Hyun; Kim, Ki Hwan; Kim, Jin-Soo; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Lung Cancer, Vol.136, pp.122-128	DOI
2019-11	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? Yoo, Shin Hye; Ock, Chan-Young; Keam, Bhumsuk; Park, Sung Joon; Kim, Tae Min; Kim, Jin Ho; Jeon, Yoon Kyung; Chung, Eun-Jae; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Jung, Kyeong Chun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.6, pp.1313-1323	view file DOI
2019-11	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis Park, Changhee; Keam, Bhumsuk; Yoon, Soon Ho; Ock, Chan-Young; Choi, Sun Mi; Kim, Miso; Park, Young Sik; Kim, Tae Min; Oh, Do-Youn; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog; Bang, Yung-Jue Esmo Open, Vol.4 No.6, p. e000575	DOI
2019-11	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer Heo, Ja Yoon; Park, Changhee; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Kim, Se Hyun; Kim, Yu Jung; Lee, Jong Seok; Heo, Dae Seog Thoracic Cancer, Vol.10 No.11, pp.2117-2123	view file DOI
2020	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma Park, Changhee; Na, Kwon Joong; Choi, Hongyoon; Ock, Chan-Young; Ha, Seunggyun; Kim, Miso; Park, Samina; Keam, Bhumsuk; Kim, Tae Min; Paeng, Jin Chul; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Cheon, Gi-Jeong; Kang, Keon Wook; Kim, Young Tae; Heo, Dae Seog Theranostics, Vol.10 No.23, pp.10838-10848	view file DOI
2020-01	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial Lee, Gyeong-Won; Go, Se-Il; Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; An, Ho Jung; Jang, Joung Soon; Kim, Bong-Seog; Hahn, Seokyung; Heo, Dae Seog Thoracic Cancer, Vol.11 No.1, pp.62-71	DOI
2020-03	Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies Park, Changhee; Kim, Miso; Kim, Min Jung; Kim, Hyeongmin; Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Jong-Il; Heo, Dae Seog Molecular Cancer Therapeutics, Vol.19 No.3, pp.937-944	DOI
2020-11	Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: An analysis of a prospectively immunoprofiled cohort Han, Bogyeong; Kim, Sehui; Koh, Jiwon; Yim, Jeemin; Lee, Cheol; Heo, Dae Seog; Kim, Tae Min; Paik, Jin Ho; Jeon, Yoon Kyung Cancers, Vol.12 No.11, pp.3305-15	DOI
2020-12	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 Kim, Miso; Keam, Bhumsuk; Ock, Chan-Young; Kim, Se Hyun; Kim, Yu Jung; Lim, Sun Min; Kim, Jin-Soo; Kim, Tae Min; Hong, Sook-Hee; Ahn, Mi Sun; Shin, Seong Hoon; Kang, Eun Joo; Kim, Dong-Wan; Im, Sun-Wha; Kim, Jong-Il; Lee, Jong Seok; Kim, Joo-Hang; Heo, Dae Seog Thoracic Cancer, Vol.11 No.12, pp.3482-3489	DOI
2021-01	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients Heo, Ja Yoon; Yoo, Shin Hye; Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Scientific Reports, Vol.11 No.1, p. 2514	DOI
2021-02	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma Kang, Minsu; Park, Changhee; Kim, Se Hyun; Yoon, Sock Won; Suh, Koung Jin; Kim, Yu Jung; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Translational Lung Cancer Research, Vol.10 No.2, pp.699-711	DOI
2021-03	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer Jung, Eun Hee; Jang, Hee Ryeong; Kim, Se Hyun; Suh, Koung Jin; Kim, Yu Jung; Lee, Ju-Hyun; Chung, Jin-Haeng; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Thoracic Cancer, Vol.12 No.5, pp.619-630	DOI
2021-06	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues Yoo, Shin Hye; Yun, Jihui; Keam, Bhumsuk; Hong, Seung-Pyo; Ock, Chan-Young; Koh, Jaemoon; Kim, Sehui; Jeon, Yoon Kyung; Jung, Kyeong Cheon; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Kim, Jong-Il; Heo, Dae Seog Cancer Immunology, Immunotherapy, Vol.70 No.6, pp.1755-1769	DOI
2021-06	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy Park, Changhee; Jeong, Kyeonghun; Park, Joon-Hyeong; Jung, Sohee; Bae, Jeong Mo; Kim, Kwangsoo; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Lee, Ju-Seog; Kim, Dong-Wan; Kang, Gyeong Hoon; Chung, Doo Hyun; Heo, Dae Seog Cancer Immunology, Immunotherapy, Vol.70 No.6, pp.1605-1617	DOI
2021-07	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer Nam, Chang Hyun; Koh, Jaemoon; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.36 No.4, pp.975-984	DOI
2021-10	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment Oh, So Yeon; Kim, Soyeon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Scientific Reports, Vol.11 No.1, p. 19712
2021-11	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC Park, Ha-Ram; Kim, Tae Min; Lee, Yusoo; Kim, Soyeon; Park, Seongyeol; Ju, Young Seok; Kim, Miso; Keam, Bhumsuk; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.16 No.11, pp.1859-1871	DOI
2022-01	Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer Lee, Chaelin; Kim, Miso; Kim, Dong-Wan; Kim, Tae Min; Kim, Soyeon; Im, Sun-Wha; Jeon, Yoon Kyung; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Cancer Research and Treatment, Vol.54 No.1, pp.140-149	DOI
2022-01	Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea Kim, Dalyong; Yoo, Shin Hye; Seo, Seyoung; Lee, Hyun Jung; Kim, Min Sun; Shin, Sung Joon; Lim, Chi-Yeon; Kim, Do Yeun; Heo, Dae Seog; Lim, Chae-Man Cancer Research and Treatment, Vol.54 No.1, pp.20-29	DOI
2022-05	Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab Park, Jun Won; Curtis, Jeffrey R.; Jun, Kang Il; Kim, Tae Min; Heo, Dae Seog; Ha, Jongwon; Suh, Kyung-Suk; Lee, Kwang-Woong; Lee, Hajeong; Yang, Jaeseok; Kim, Min Jung; Choi, Yunhee; Lee, Eun Bong Chest, Vol.161 No.5, pp.1201-1210	DOI
2023-01	The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines Lee, Jeongjae; Keam, Bhumsuk; Kim, Soyeon; Heo, Jung-Nyoung; Joung, Eunkyo; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Translational Oncology, Vol.27, p. 101592	DOI
2023-10	Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Kim, Miso; Kim, Soyeon; Yim, Jeemin; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.55 No.4, pp.1134-1143	DOI

1 2 3 4